Get started

Financials · AGIO

Agios Pharmaceuticals Inc. (AGIO) financials

For the twelve months ended Sep 30, 2026, Agios Pharmaceuticals Inc. reported $140.84M of revenue and -$372.90M of net income.

Revenue, TTM
$140.84M
Revenue growth, YoY
+214.4%
Net income, TTM
-$372.90M
Net margin
-264.8%
Free cash flow, TTM
-$335.97M
EPS, diluted, TTM
-$6.33
Cash
$128.55M
P/S
12.46
Market cap
$1.76B
Annual revenue$54.03M
FY2016FY2025
Annual net income-$412.78M
FY2016FY2025
Annual free cash flow-$377.29M
FY2016FY2025

AGIO revenue and earnings growth

AGIO revenueQ3 2026$55.38M

Quarter YoY
+330.0%
QoQ
+23.8%
FY YoY
+48.0%
10Y CAGR
-0.9%

AGIO revenue was $55.38M in fiscal Q3 2026 (ended Sep 30, 2026), up 330.0% from a year earlier and up 23.8% from the prior quarter. For the full fiscal 2025 it was $54.03M, up 48.0% from fiscal 2024. Compound annual growth was -0.9% over 10 years. It rose in each of the last 3 fiscal years.

AGIO net incomeQ3 2026-$65.05M

AGIO net income was -$65.05M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$103.43M a year earlier. For the full fiscal 2025 it was -$412.78M, compared with $673.73M in fiscal 2024.

AGIO EPSQ3 2026-$1.09

AGIO diluted EPS was -$1.09 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.78 a year earlier. For the full fiscal 2025 it was -$7.12, compared with $11.64 in fiscal 2024.

AGIO free cash flowQ3 2026-$60.42M

AGIO free cash flow was -$60.42M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$89.71M a year earlier. For the full fiscal 2025 it was -$377.29M, compared with -$391.53M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$54.03M$36.50M$26.82M$14.24M$0$0$117.91M$94.39M$43.01M$69.89M
Cost of revenue$6.34M$4.17M$2.88M$1.70M$0$0$1.32M$1.40M$0$0
Gross profit$47.68M$32.33M$23.94M$12.54M$0$0$116.59M$92.99M$43.01M$69.89M
Research and development$339.54M$301.29M$295.53M$279.91M$256.97M$220.81M$214.26M$341.32M$292.68M$220.16M
Selling, general and admin$180.28M$156.78M$119.90M$121.67M$121.44M$115.11M$102.01M$114.14M$71.12M$50.71M
Operating income-$472.13M-$425.74M-$391.49M-$389.05M-$378.42M-$335.92M-$316.27M-$362.48M-$320.79M-$200.99M
Pre-tax income-$413.80M$717.97M-$352.09M-$231.80M-$356.51M-$329.31M-$301.41M-$346.03M-$314.67M-$198.47M
Income tax-$1.02M$44.24M$0$0--$0$0$0$0
Net income-$412.78M$673.73M-$352.09M-$231.80M$1.60B-$327.37M-$411.47M-$346.03M-$314.67M-$198.47M
EPS, basic-$7.12$11.86-$6.33-$4.23$26.55-$4.74-$6.86-$6.03-$6.75-$5.07
EPS, diluted-$7.12$11.64-$6.33-$4.23$26.55-$4.74-$6.86-$6.03-$6.75-$5.07
Diluted shares58.0M57.9M55.7M54.8M60.4M69.0M60.0M57.4M46.6M39.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$89.13M$76.25M$88.20M$139.26M$203.13M$127.44M$80.93M$70.50M$102.72M$160.75M
Inventory$32.92M$27.62M$19.08M$8.49M$0$14.70M$7.33M$869.0K$0-
Current assets$942.05M$965.60M$833.84M$832.77M$1.06B$636.68M$611.70M$613.78M$445.26M$559.89M
Total assets$1.30B$1.66B$937.12M$1.24B$1.44B$852.95M$890.74M$858.46M$614.40M$619.09M
Current liabilities$82.21M$81.16M$67.95M$62.63M$59.83M$94.39M$92.89M$93.50M$94.94M$88.43M
Total liabilities$104.11M$122.24M$126.10M$137.90M$145.76M$453.45M$250.21M$170.92M$238.89M$260.50M
Shareholders' equity$1.19B$1.54B$811.02M$1.10B$1.29B$399.50M$640.53M$687.54M$375.50M$358.59M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$372.98M-$389.84M-$296.06M-$309.48M-$407.32M-$290.76M-$370.62M-$304.42M-$285.23M$38.56M
Capital expenditures$4.32M$1.69M$999.0K$4.88M$5.74M$14.11M$12.03M$6.99M$4.63M$9.91M
Free cash flow-$377.29M-$391.53M-$297.06M-$314.36M-$413.06M-$304.87M-$382.65M-$311.41M-$289.86M$28.65M
Investing cash flow$377.18M$363.44M$239.57M$243.26M$1.25B$75.75M$91.44M-$273.82M-$57.91M-$119.35M
Financing cash flow$8.68M$14.44M$5.43M$2.35M-$765.77M$261.52M$289.61M$546.02M$285.11M$169.78M
Stock-based compensation$52.55M$42.85M$44.77M$49.30M$53.51M$61.60M$58.05M$73.36M$47.81M$42.09M
Depreciation and amortization------$8.09M$7.17M$6.43M-

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY48.0%36.1%88.4%---100.0%24.9%119.4%-38.5%18.2%
Gross margin88.3%88.6%89.3%88.0%--98.9%98.5%100.0%100.0%
Operating margin-873.9%-1166.5%-1459.5%-2732.1%---268.2%-384.0%-745.8%-287.6%
Net margin-764.0%1845.9%-1312.6%-1627.8%---349.0%-366.6%-731.6%-284.0%
Free cash flow margin-698.3%-1072.7%-1107.5%-2207.6%---324.5%-329.9%-673.9%41.0%
Return on equity-34.6%43.7%-43.4%-21.1%124.2%-81.9%-64.2%-50.3%-83.8%-55.3%
Return on assets-31.8%40.5%-37.6%-18.7%111.6%-38.4%-46.2%-40.3%-51.2%-32.1%
Current ratio11.4611.9012.2713.3017.796.746.596.564.696.33

Source: XBRL data Agios Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

AGIO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
AGIO$140.84M+214.4%-$372.90M-264.8%$1.76B
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

AGIO FAQ

9 questions
  • What is AGIO revenue?
    Agios Pharmaceuticals Inc. (AGIO) reported $140.84M of revenue for the twelve months ended Sep 30, 2026. That is up 214.4% from the year before. Revenue for fiscal 2025 was $54.03M.
  • Is AGIO profitable?
    No. Agios Pharmaceuticals Inc. reported a net loss of $372.90M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does AGIO have?
    Agios Pharmaceuticals Inc. reported $128.55M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is AGIO revenue growing?
    Agios Pharmaceuticals Inc.'s revenue changed +48.0% in fiscal 2025, to $54.03M. Its compound annual growth rate was -0.9% over 10 years.
  • What is AGIO gross margin?
    Agios Pharmaceuticals Inc.'s gross profit was $132.12M on $140.84M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 93.8%.
  • What is AGIO free cash flow?
    Agios Pharmaceuticals Inc. generated -$335.97M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$331.68M less capital expenditures.
  • What is AGIO earnings per share?
    Diluted earnings per share were -$6.33 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did AGIO last report financial results?
    The latest statements here come from Agios Pharmaceuticals Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this AGIO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Agios Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.